Tenon Medical, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
TNON$1.75+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except share data)
| December 31, | December31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,756 | $6,535 |
| Accounts receivable, net | 1,698 | 863 |
| Inventory | 1,054 | 606 |
| Prepaid expenses and other current assets | 260 | 206 |
| Total current assets | 6,768 | 8,210 |
| Property and equipment, net | 918 | 752 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 131 | 399 |
| Deferred offering costs | — | 431 |
| Intangible assets, net (Notes 3 and 6) | 485 | — |
| Goodwill (Note 3) | 2,407 | — |
| TOTAL ASSETS | $10,760 | $9,843 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $845 | $369 |
| Accrued expenses | 1,637 | 910 |
| Current portion of accrued commissions | 590 | 303 |
| Current portion of operating lease liability | 141 | 287 |
| Total current liabilities | 3,213 | 1,869 |
| Accrued commissions, net of current portion | 1,514 | 1,862 |
| Operating lease liability, net of current portion | — | 141 |
| Contingent consideration (Note 3) | 993 | — |
| Total liabilities | 5,720 | 3,872 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at December 31, 2025 and 2024; 204,159 and 256,968 shares issued and outstanding at December 31, 2025 and 2024, respectively | 2,622 | 3,300 |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at December 31, 2025 and 2024; 86,454 shares issued and outstanding at December 31, 2025 and 2024 | 452 | 452 |
| Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2025 and 2024; 10,851,273 and 3,138,804 shares issued and outstanding at December 31, 2025 and 2024, respectively | 11 | 3 |
| Additional paid-in capital | 83,257 | 70,962 |
| Accumulated deficit | (81,302) | (68,746) |
| Total stockholders’ equity | 5,040 | 5,971 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $10,760 | $9,843 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.